Merck & Co. (NYSE:MRK) reported third-quarter 2026 earnings and revenue above analysts’ expectations on Thursday and increased its full-year profit outlook. Shares of the pharmaceutical company advanced more than 2% in premarket trading following the announcement.
Earnings per share reached $2.49, exceeding the consensus estimate of $2.09. Quarterly revenue totaled $18.1 billion, representing growth of 4% excluding foreign exchange effects and surpassing analysts’ expectations of $17.28 billion.
Merck’s cancer immunotherapy Keytruda generated third-quarter revenue of $8.6 billion, an increase of 6% compared with the previous year.
The total included $830 million in sales from Keytruda Qlex, the company’s newer subcutaneous formulation of the treatment.
Winrevair, Merck’s therapy for pulmonary arterial hypertension, recorded revenue of $694 million, representing a 93% year-over-year increase.
Gardasil and Gardasil 9 vaccine sales rose 14% excluding currency fluctuations to approximately $2 billion.
Meanwhile, the company’s Animal Health division reported revenue of $1.7 billion, an increase of 4%.
Merck also discussed developments within its oncology research pipeline, including clinical data presented at the recent European Society for Medical Oncology (ESMO) meeting.
Chief Executive Officer Robert Davis commented:
“Our science-led strategy is transforming our business. The potentially practice-changing advances in oncology presented at last weekend’s ESMO meeting, including new data for our antibody-drug conjugate sac-TMT and the first Phase 3 validation of a therapeutic cancer vaccine, further clinically de-risk the substantial long-term opportunity of our late-phase pipeline.”
The company highlighted results involving sac-TMT, an investigational antibody-drug conjugate, alongside Phase 3 clinical findings for a therapeutic cancer vaccine.
Merck increased its 2026 earnings per share forecast to a range of $2.77 to $2.82, compared with its previous guidance of $2.66 to $2.76.
The revised range is above analysts’ consensus estimate of $2.65 per share.
The company also narrowed its annual revenue guidance to between $66.8 billion and $67.3 billion.
The midpoint of the revised revenue forecast, $67.05 billion, is broadly consistent with the market consensus of $67.04 billion.
The updated guidance follows third-quarter results that exceeded earnings and revenue expectations, with Keytruda, Winrevair and the company’s vaccine portfolio contributing to reported sales.
Merck stock price
| Nov-18 | |
| Nov-18 | |
| Nov-18 | |
| Nov-17 | |
| Nov-17 | |
| Nov-16 | |
| Nov-13 | |
| Nov-13 | |
| Nov-12 | |
| Nov-12 | |
| Nov-12 | |
| Nov-12 | |
| Nov-11 | |
| Nov-11 | |
| Nov-09 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite